NASDAQ Companies

Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer Biomea preparing icovamenib for late-stage clinical development Multiple milestones anticipated in 2025 […]

CLAYMONT, Del., March 31, 2025 (GLOBE NEWSWIRE) — Archimedes Tech SPAC Partners II Co. (Nasdaq: ATIIU) (the “Company”) today announced […]

Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome […]

-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial – – […]

CAMARILLO, Calif., March 31, 2025 (GLOBE NEWSWIRE) — via IBN – Newton Golf Company (Nasdaq: NWTG), a developer of performance-focused […]

SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the […]

Dubai, March 31, 2025 – VEON Ltd. (Nasdaq: VEON), a global digital operator, (“VEON” or the “Company”), today announced that […]

CNOVA N.V.Information regarding buy-out of minority shareholders, suspension of trading and delisting AMSTERDAM – 31 March 2025, 18:15 CET Cnova […]

WASHINGTON, March 31, 2025 (GLOBE NEWSWIRE) — ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or the “Company”), announced that it […]

REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) — Check Point Software Technologies Ltd. (NASDAQ: CHKP), a pioneer and global […]